Matching articles for "FluceIvax"

Influenza Vaccine for 2022-2023

   
The Medical Letter on Drugs and Therapeutics • October 3, 2022;  (Issue 1660)
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023...
Annual vaccination in the US against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Influenza vaccines that are available in the US for the 2022-2023 season are listed in Table 2.
Med Lett Drugs Ther. 2022 Oct 3;64(1660):153-7 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2021-2022

   
The Medical Letter on Drugs and Therapeutics • October 4, 2021;  (Issue 1634)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.
Med Lett Drugs Ther. 2021 Oct 4;63(1634):153-7 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2020-2021

   
The Medical Letter on Drugs and Therapeutics • September 21, 2020;  (Issue 1607)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Vaccination of all eligible persons can reduce the prevalence of influenza illness...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Vaccination of all eligible persons can reduce the prevalence of influenza illness and symptoms that might be confused with those of COVID-19. Available vaccines and recommendations for specific patient populations for the 2020-2021 season are listed in Tables 2 and 3. Lower rates of influenza illness have been observed this season in the Southern Hemisphere, probably because of masking, social distancing, school closures, and travel restrictions.
Med Lett Drugs Ther. 2020 Sep 21;62(1607):145-50 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2019-2020

   
The Medical Letter on Drugs and Therapeutics • October 21, 2019;  (Issue 1583)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Available vaccines and recommendations for specific patient populations for the...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Available vaccines and recommendations for specific patient populations for the 2019-2020 season are listed in Tables 2 and 3.
Med Lett Drugs Ther. 2019 Oct 21;61(1583):161-6 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2018-2019

   
The Medical Letter on Drugs and Therapeutics • October 22, 2018;  (Issue 1558)
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old. Recommendations for the current season for specific patient populations are listed in Tables 2 and...
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old. Recommendations for the current season for specific patient populations are listed in Tables 2 and 4.
Med Lett Drugs Ther. 2018 Oct 22;60(1558):169-73 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2017-2018

   
The Medical Letter on Drugs and Therapeutics • October 9, 2017;  (Issue 1531)
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific...
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Med Lett Drugs Ther. 2017 Oct 9;59(1531):163-6 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2016-2017

   
The Medical Letter on Drugs and Therapeutics • October 10, 2016;  (Issue 1505)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Med Lett Drugs Ther. 2016 Oct 10;58(1505):127-30 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2015-2016

   
The Medical Letter on Drugs and Therapeutics • September 14, 2015;  (Issue 1477)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Med Lett Drugs Ther. 2015 Sep 14;57(1477):125-7 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2014-2015

   
The Medical Letter on Drugs and Therapeutics • October 13, 2014;  (Issue 1453)
Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and...
Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications.
Med Lett Drugs Ther. 2014 Oct 13;56(1453):97-9 | Show Full IntroductionHide Full Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • June 1, 2014;  (Issue 142)
Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately. Eight vaccines are currently recommended by the US Advisory Committee on...
Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately.

Eight vaccines are currently recommended by the US Advisory Committee on Immunization Practices (ACIP) for routine use in adults at various ages...
Treat Guidel Med Lett. 2014 Jun;12(142):39-48 | Show Full IntroductionHide Full Introduction

Influenza Vaccine for 2013-2014

   
The Medical Letter on Drugs and Therapeutics • September 16, 2013;  (Issue 1425)
Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications. Several new vaccines are available for the current...
Annual vaccination against influenza A and B viruses has been shown to decrease influenza illness and its complications. Several new vaccines are available for the current season.
Med Lett Drugs Ther. 2013 Sep 16;55(1425):73-5 | Show Full IntroductionHide Full Introduction

In Brief: Two New Seasonal Influenza Vaccines

   
The Medical Letter on Drugs and Therapeutics • February 4, 2013;  (Issue 1409)
Two new trivalent influenza vaccines, Flucelvax (Novartis) and Flublok (Protein Sciences), will soon be available for prevention of seasonal influenza in adults ≥18 years old (Flucelvax) and 18-49 years old...
Two new trivalent influenza vaccines, Flucelvax (Novartis) and Flublok (Protein Sciences), will soon be available for prevention of seasonal influenza in adults ≥18 years old (Flucelvax) and 18-49 years old (Flublok). Unlike other available influenza vaccines, neither vaccine is produced in eggs, removing any concern regarding use in egg-allergic patients. Avoiding the use of eggs should allow for faster production of these 2 new vaccines, which could be especially beneficial during a pandemic.

Flucelvax is prepared in a similar manner to other influenza vaccines, but the influenza virus is grown in canine kidney cell culture instead of chicken eggs. In an unpublished study summarized in the package insert comparing Flucelvax with placebo in more than 11,000 patients during the 2007-2008 season, the new vaccine was effective in preventing about 84% of cases of influenza due to matching strains and was about 70% effective when non-matching strains were included.

Flublok is produced without use of influenza virus or chicken eggs; a gene that encodes for hemagglutinin antigen (HA) is introduced into baculovirus, a virus that infects insect cells, and the replicating baculovirus produces large amounts of HA. In a study in about 4,600 adults conducted during one influenza season, Flublok was about 45% effective compared to placebo in preventing culture-confirmed influenza despite a significant antigenic mismatch between the vaccine and circulating viruses (96% of circulating strains did not match the vaccine). It was 75% effective in preventing illness caused by matching strains.1

Both Flublok and Flucelvax provide protection against the same strains as the other vaccines available for the 2012-2013 influenza season.2

1. JJ Treanor et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733.

2. Influenza vaccine 2012-2013. Med Lett Drugs Ther 2012; 54:77.

Download complete U.S. English article

Med Lett Drugs Ther. 2013 Feb 4;55(1409):12 | Show Full IntroductionHide Full Introduction